Premium
Cell‐mediated immunity in patients with carcinoma. Correlation between clinical stage and immunocompetence
Author(s) -
Kopersztych Samuel,
Rezkallah Maria Thereza,
Miki Silvia S.,
Naspitz Charles K.,
Mendes Nelson F.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197609)38:3<1149::aid-cncr2820380316>3.0.co;2-x
Subject(s) - immunocompetence , medicine , immunology , antigen , immunity , delayed hypersensitivity , in vivo , cellular immunity , sensitization , cell mediated immunity , t cell , immune system , biology , microbiology and biotechnology
Cell‐mediated immunity (CMI) was evaluated in 82 patients with non‐lymphoid tumors by in vivo and in vitro methods. These included skin test with ubiquitous antigens, 2,4 dinitrochlorobenzene (DNCB) sensitization, determination of T and B peripheral blood lymphocytes, and lymphocyte response to phytohemagglutinin (PHA). The patients were divided into two groups: those with localized and those with disseminated disease (LD and DD). The patients with LD showed no significant differences in CMI when compared with normal controls. The patients with DD showed various defects in CMI when compared with controls and patients with LD. There were significant differences in the response to DNCB, and streptokinase‐streptodornase (SKSD) was the most discriminative of the skin‐test antigens. The response to PHA was greatly depressed in patients with DD, whether in the presence of autologous or homologous plasma; in some patients a factor inhibiting to blastogenesis was detected in the serum. In patients with DD, a T‐cell lymphopenia was observed. These data showed a correlation between immunocompetence and clinical stage.